Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
about
Progress in Treatment of Viral Infections in Children with Acute Lymphoblastic LeukemiaPreventing stem cell transplantation-associated viral infections using T-cell therapyCord blood graft engineeringNovel immunotherapies for hematologic malignanciesImmunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapiesAntiviral T-cell therapyAdoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesToward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution.Engineering cord blood to improve engraftment after cord blood transplant.Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantationControlling cytomegalovirus: helping the immune system take the leadLow rate of infusional toxicity after expanded cord blood transplantation.Immunotherapy: opportunities, risks and future perspectivesSuccessful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.Concise review: umbilical cord blood transplantation: past, present, and futureGeneration of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplantCytolytic T lymphocytes from HLA-B8+ donors frequently recognize the Hodgkin's lymphoma associated latent membrane protein 2 of Epstein Barr virus.Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients.Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation.The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodGraft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMVCMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.T-cell therapy for viral infections following transplantation: why stop at three viruses?Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic Hematopoietic Stem Cell TransplantationDissecting graft-versus-leukemia from graft-versus-host-disease using novel strategiesEarly CD3 peripheral blood chimerism predicts the long-term engrafting unit following myeloablative double-cord blood transplantation.Unrelated umbilical cord blood transplantation and immune reconstitution.Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation.T cells for viral infections after allogeneic hematopoietic stem cell transplant
P2860
Q26740588-BB55F3FC-56C1-4B5E-9895-C83A3E92E1E5Q26801365-C0DF6B59-E10C-466C-BACF-00B32B6379DEQ26822376-022B764F-3EE6-4D52-BB4B-C73EDBF31167Q27004436-AA3BE9C5-40C4-406E-B79D-06A619B85AE8Q27027243-A3181EF1-3E40-41E3-992C-18B602769725Q27028006-0A2FC8D9-EBB8-444F-836F-A6B4F2A88228Q29393780-9A60DCA4-CAB2-4D27-B679-47D70035CBA5Q33633262-189F5579-730A-45FF-B134-8C70CD51C8D0Q33726613-ECFEC1DA-D3C0-4865-9991-42131E524E37Q33766995-54C42120-C14F-4519-A458-68DE1A411CFCQ33780277-AEAF1DBE-0E0A-4FFF-B38E-B6DB8BEE7032Q33820695-5377B590-049E-421B-B287-BD9A41EC6FA6Q33864607-2559B612-01B6-44C9-81DA-72EAF689E063Q33941012-F97D8CEB-B103-454A-9F4B-3BB81CDC8654Q34450754-E49F4D9E-37AA-479B-9072-4CB6898AD3ABQ34557953-F7CC75CA-F457-42DD-A147-F6090A57FA6BQ34601968-19E1ACFF-ABDB-4F20-ACE1-89E54FB4BB98Q34635978-9AA4A8F6-F785-4BCA-8D26-857C5706BDF7Q34712758-5E9839B9-CB4C-41E6-B1E2-B858382A7789Q34803707-030D374F-4584-42CE-82A3-7D1EB2178980Q34923734-FE08C333-5327-4850-A726-3AB8F2B41F8DQ35285087-B17648FD-24B3-4D40-A288-703C917669CFQ35308252-F48FAA17-4EC0-4520-90CA-8DB3F62F950FQ35477534-B6AF284E-0694-41FE-92E6-56EA38E1E5EBQ35514288-39BE73B0-AD92-45DD-BFFC-9CDC7EF041C1Q35556061-33BCB341-2160-4358-A550-82336DD6F7A0Q35582326-E311EA32-0012-4824-A3F0-5718C6A1A01AQ35591430-62FE1225-9686-4CBA-88C9-79948D339CD6Q35653249-F698E3AE-68EE-437C-8184-BD6AB56E6E1FQ35665033-3A18C345-E384-4674-AC8A-F4DC9CE50C38Q35776868-A9E54FE0-C317-45FB-80E9-BD006F308D58Q36142522-9EC570B5-F98E-4EB2-9FD1-77BC79D37D86Q36276185-9D83630A-B4AB-444D-9D11-32B6228F311FQ36305254-5F7E9697-206A-42B1-93ED-CE2E41FE7837Q36578672-723523A5-388D-48D9-9ECB-060FFF5A6950Q36819337-6B5C443A-3745-452B-A164-45A550B2756EQ36923420-CAD1C00E-DED8-4348-9487-077C191F6665Q36934304-6F7939E1-75F3-4DF8-A126-75B9ABFEEF83Q36956443-07181276-C62F-4A77-86F9-C480FEB53728Q37058107-C9F0B59E-BF31-4B9B-B957-A89871CFFA42
P2860
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Functionally active virus-spec ...... get a range of viral epitopes.
@en
Functionally active virus-spec ...... get a range of viral epitopes.
@nl
type
label
Functionally active virus-spec ...... get a range of viral epitopes.
@en
Functionally active virus-spec ...... get a range of viral epitopes.
@nl
prefLabel
Functionally active virus-spec ...... get a range of viral epitopes.
@en
Functionally active virus-spec ...... get a range of viral epitopes.
@nl
P2093
P2860
P1433
P1476
Functionally active virus-spec ...... get a range of viral epitopes.
@en
P2093
Adrian P Gee
Ann M Leen
Barbara Savoldo
Catherine M Bollard
Cliona M Rooney
Conrad Russell Young Cruz
Elizabeth J Shpall
Gianpietro Dotti
Helen E Heslop
P2860
P304
P356
10.1182/BLOOD-2009-03-213256
P407
P577
2009-05-14T00:00:00Z